Amgen’s Biosimilar of Stelara Shows Promising Preliminary Results

New preliminary results show that Amgen’s biosimilar ABP 654 is effective in reducing psoriasis symptoms. ABP 654 is a biosimilar of Stelara, a drug currently improved and in use in 74 countries. Patients treated with the biosimilar experienced improvement in the psoriasis area severity index.

According to John Pinching of PM Live, “The phase 3 study was a multicentre, randomised, double-blinded, comparative clinical study which included 563 patients, with 281 patients in the ABP 654 group and 282 patients in the Stelara group. The participants all had moderate to severe plaque psoriasis.”

Click here to read more.

(Source: PM Live, April 20^th, 2022)